Please assess the completion status of the following clinical trial:

Trial Title: Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. diagnosis of BD I or II~3. non-remitting BD as defined by the presence of mood symptoms of at least moderate severity, indicated by a MADRS score ≥ 15 despite being on optimal treatment according to the CANMAT/APA guidelines~4. HOMA-IR ≥ 1.8, indicating IR (subjects will have FPG and FSI testing done to determine whether they have IR or T2D)~5. current episode of depression 4 weeks or longer in duration~6. on a stable optimal dose of mood stabilizing treatment for at least 4 weeks prior to study entry~Exclusion Criteria:~1. Diagnoses of organic mood disorder, mood disorder not otherwise specified, alcohol dependence, T1D or T2D~2. presence of rapid cycling (by DSM-5 criteria), mania, (indicated by a Young Mania Rating Scale \[YMRS\] score \> 15), or suicide ideation (current score of 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating scale \[C-SSRS\])~3. patient receiving metformin \< 2 weeks prior to study entry~4. metformin allergy or sensitivity~5. metformin contraindicated where liver function tests \> three times the upper limit of normal, estimated glomerular filtration rate (eGFR) \< 30, CBC revealing megaloblastic anemia or pre-existing untreated B12 deficiency~6. pregnancy or breastfeeding~7. lactose intolerance, diagnosed by a physician~8. chronic use of narcotic medications~9. patient lacks full capacity to consent to study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator to be given twice daily, once with breakfast and once with supper
- Metformin (Type: EXPERIMENTAL): Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper

Based on this trial design, predict the completion outcome and termination type (if applicable).